Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-28T17:50:05.609Z Has data issue: false hasContentIssue false

SSRIs and tricyclic antidepressants

Published online by Cambridge University Press:  02 January 2018

L. J. Ashworth
Affiliation:
The University of Liverpool Department of Psychiatry P.O. Box 147 Liverpool L69 3BX
K. C. M. Wilson
Affiliation:
The University of Liverpool Department of Psychiatry P.O. Box 147 Liverpool L69 3BX
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Copyright
Copyright © The Royal College of Psychiatrists 

References

Brosen, K., et al (1992) Pharmacogenetics of tricyclic antidepressants and novel antidepressants: recent developments. Clinical Neuropharmacology, 15, 80A81A.Google Scholar
Brosen, K. & Skelbo, E. (1990) Fluoxetine and norfluoxetine are potent inhibitors of P450—II—D6 — the source of the sparteine/debrisoquine oxidation polymorphism. British Journal of Clinical Pharmacology, 32, 136137.Google Scholar
Committee on Safety of Medicines (1989) Current Problems (May).Google Scholar
Preskorn, S. H. & Fast, G. A. (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety and cost effectiveness. Journal of Clinical Psychiatry, 52, 2333.Google Scholar
van Ameringen, M. & Mancini, C. (1992) Adverse effects of switching from fluoxetine to desipramine. Canadian Journal of Psychiatry, 37, 278.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.